GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Applied Organometallic Chemistry, Wiley, Vol. 36, No. 5 ( 2022-05)
    Abstract: A series of biologically active metal complexes was yielded from the reactions of 2‐(4‐bromophenylamino)acetohydrazide ligand (HL) with Co(II), Ni(II), Cu(II), Cd(II) chlorides, CuBr 2 , Cu(CH 3 COO) 2 , and Cu(ClO 4 ) 2 salts. The structure and stereochemistry of the afforded complexes were elucidated by means of elemental analyses, molar conductance, magnetic susceptibility, thermal analyses (TG/DTG), and spectral techniques (mass, IR, UV‐Vis, and 1 H NMR). Elemental analyses along with molar conductance data demonstrated that all metal complexes are nonelectrolyte and were formed with 1L:1M, 1L:2M, and 2L:1M stoichiometry. IR spectral data provided an evidence for the neutral bidentate behavior of the hydrazide ligand toward metal ions via carbonyl oxygen and amino nitrogen atoms (ON donor). Magnetic susceptibility along with electronic absorption spectral results authenticated that all complexes have an octahedral geometry except, CuCl 2 complex (3) , which possessed a square planar one. The hydrazide ligand and some of its synthesized metal complexes were screened in vitro for their antitumor and apoptotic activity. The results showed that CuBr 2 complex (4) has promising anticancer activities against breast MCF7, liver HepG2, and colorectal HCT 116 cancerous cells through induction of proapoptotic gene (Bax) and inhibit the antiapoptotic gene (Bcl‐2), thus increase the Bax/Bcl‐2 ratio. Moreover, these newly synthesized compounds were most potent and can be used as a therapeutic chemoprevention against these cancerous cells compared with doxorubicin (DOX), the currently available anticancer drug against solid tumors.
    Type of Medium: Online Resource
    ISSN: 0268-2605 , 1099-0739
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2022
    detail.hit.zdb_id: 1480791-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Journal of Medical Virology, Wiley, Vol. 93, No. 10 ( 2021-10), p. 5833-5838
    Abstract: Researchers around the world are working at record speed to find the best ways to treat and prevent coronavirus disease 2019 (COVID‐19). This study aimed to evaluate the efficacy of ivermectin for the treatment of hospitalized mild to moderate COVID‐19 infected patients. This was a randomized open‐label controlled study that included 164 patients with COVID‐19. Patients were randomized into two groups where Group 1 (Ivermectin group) included patients who received ivermectin 12 mg once daily for 3 days with standard care and Group 2 (control group) included patients who received standard protocol of treatment alone for 14 days. The main outcomes were mortality, the length of hospital stay, and the need for mechanical ventilation. All patients were followed up for 1 month. Overall, 82 individuals were randomized to receive ivermectin plus standard of care and 82 to receive standard of care alone. Patients in the ivermectin group had a shorter length of hospital stay (8.82 ± 4.94 days) than the control group (10.97 ± 5.28 days), but this was not statistically significant ( p  = 0.085). Three patients (3.7%) in each group required mechanical ventilation ( p  = 1.00). The death rate was three patients in the ivermectin group (3.7%) versus four patients (4.9%) in the control group without any significant difference between the two groups ( p  = 1.00). Although there was no statistically significant difference in any endpoints by ivermectin doses (12 mg/day for 3 days); there was an observed trend to reducing hospital stay in the ivermectin‐treated group.
    Type of Medium: Online Resource
    ISSN: 0146-6615 , 1096-9071
    URL: Issue
    RVK:
    Language: English
    Publisher: Wiley
    Publication Date: 2021
    detail.hit.zdb_id: 752392-0
    detail.hit.zdb_id: 1475090-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...